Cite
HARVARD Citation
Quinn, D. et al. (2018). Pharmacodynamics, pharmacokinetics and safety of revefenacin (TD-4208), a long-acting muscarinic antagonist, in patients with chronic obstructive pulmonary disease (COPD): Results of two randomized, double-blind, phase 2 studies. Pulmonary pharmacology & therapeutics. pp. 71-79. [Online].